RISTEMPA

This brand name is authorized in Australia, Estonia, Lithuania

Active ingredients

The drug RISTEMPA contains one active pharmaceutical ingredient (API):

1 Pegfilgrastim
UNII 3A58010674 - PEGFILGRASTIM

Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.

Read about Pegfilgrastim

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L03AA13 Pegfilgrastim L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 6363X, 9514R
Country: EE Ravimiamet Identifier(s): 1683154
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1076162, 1076163, 1076164

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈